| Literature DB >> 31098338 |
Palanisamy Ravichandiran1, Maciej Masłyk2, Sunirmal Sheet3, Monika Janeczko2, Dhanraj Premnath4, Ae Rhan Kim5, Byung-Hyun Park6, Myung-Kwan Han7, Dong Jin Yoo1.
Abstract
1,4-Naphthoquinones are an important class of compounds present in a number of natural products. In tEntities:
Keywords: antimicrobial activity; hemolysis; naphthoquinone derivatives; necrosis; reactive oxygen species
Year: 2019 PMID: 31098338 PMCID: PMC6507621 DOI: 10.1002/open.201900077
Source DB: PubMed Journal: ChemistryOpen ISSN: 2191-1363 Impact factor: 2.911
Figure 1Important nitrogen and sulfur containing naphthoquinones possesses interesting antimicrobial properties.
Scheme 1Synthesis and substrate scope of 2‐((4‐((4‐aminophenyl)sulfonyl)phenyl)amino)‐3‐(cyclohexylthio)naphthalene‐1,4‐diones (3–5 w).
Scheme 2Synthesis of 2‐(cyclohexylthio)‐3‐(phenylamino)naphthalene‐1,4‐diones (5 x–5 aa).
In vitro antibacterial activity of 1,4‐naphthoquinone derivatives (3–5 aa) expressed as minimal inhibitory concentration.
| MIC (μg/mL) | ||||||||
|---|---|---|---|---|---|---|---|---|
| Compd. |
|
|
|
|
|
|
|
|
| 3 | 150±0.23 | >300 | NA | NA | NA | >300 | >300 | >300 |
| 4 | >300 | >300 | 150±0.12 | 300±0.89 | 150±0.81 | 150±0.13 | 150±0.27 | >300 |
| 5 a | 150±0.19 | >300 | NA | NA | >300 | >300 | NA | NA |
| 5 b |
| >300 | >300 | 300±0.71 | >300 | >300 | 300±0.19 | >300 |
| 5 c |
| >300 | >300 | 150±0.09 | 150±0.11 | 150±0.84 | >300 | >300 |
| 5 d | 150±1.10 | >300 | 150±0.21 | 150±0.80 | 150±0.08 | >300 | >300 | >300 |
| 5 e | 150±1.01 | >300 | 300±0.99 |
| 300±0.41 | >300 | >300 | >300 |
| 5 f |
| >300 | >300 | NA | >300 | >300 | >300 | >300 |
| 5 g | 150±0.19 | >300 | 150±1.10 | 150±0.91 | 150±0.14 | >300 | >300 | >300 |
| 5 h | NA | >300 | >300 | >300 | NA | >300 | >300 | NA |
| 5 i | 150±0.70 | 150±0.27 | 150±0.78 | 150±0.83 | 150±0.70 | >300 | 150±0.18 | >300 |
| 5 j |
| >300 |
| >300 | >300 | >300 | >300 | >300 |
| 5 k | NA | >300 | >300 | >300 | >300 | NA | >300 | >300 |
| 5 l | >300 | >300 | >300 | >300 | >300 | >300 | >300 | >300 |
| 5 m | >300 | >300 | >300 | >300 | NA | >300 | >300 | >300 |
| 5 n | 300±0.92 | >300 | >300 | >300 | NA | >300 | >300 | NA |
| 5 o | >300 | >300 | >300 | >300 | >300 | >300 | >300 | >300 |
| 5 p | >300 | >300 | >300 | >300 | >300 | NA | >300 | >300 |
| 5 q |
| >300 | 300±0.28 | 300±0.90 | 300±0.69 | >300 | >300 | >300 |
| 5 r | 150±0.91 | >300 | 300±0.20 | 300±0.82 | 300±0.12 | >300 | >300 | >300 |
| 5 s | 150±0.11 | >300 | >300 | >300 | >300 | NA | >300 | >300 |
| 5 t | 150±0.81 | >300 | >300 | >300 | NA | >300 | >300 | NA |
| 5 u | 150±0.99 | >300 | 150±0.12 | 150±0.97 | 150±0.44 | 150±0.25 | >300 | >300 |
| 5 v |
| >300 |
| >300 | 150±0.10 | >300 | >300 | >300 |
| 5 w | 150±0.85 | >300 | 300±0.11 | 300±1.41 | >300 | >300 | 300±0.55 | >300 |
| 5 x | 300±0.89 | >300 | >300 | >300 | >300 | >300 | >300 | NA |
| 5 y |
| >300 | 300±1.60 | 300±1.30 | 300±0.41 | >300 | >300 | >300 |
| 5 z | >300 | NA | >300 | >300 | NA | >300 | >300 | NA |
| 5 aa | >300 | >300 | NA | >300 | NA | >300 | >300 | >300 |
| Caspofungin | >300 | >300 | >300 | >300 | >300 | >300 | >300 | >300 |
| Amphotericin B | NA | NA | NA | NA | NA | NA | NA | 0.1±0.19 |
| Chloramphenicol | NA | NA | NA | NA | NA | NA | NA | 2±0.76 |
| Streptomycin | 7.8±0.15 | 1.9±1.10 | 7.8±0.71 | 10.2±0.92 | 7.8±0.70 | 7.8±0.91 | 3.2±0.40 | 1.5±0.19 |
Results expressed in μg/mL; Concentration range used: 0.001–2 mg/mL; NA – No Activity; entries in boldface highlight MIC values <70 μg/mL.
Figure 2Hemolytic activity of compounds 5 b, 5 c, 5 f, 5 j, 5 q, 5 v, and 5 y. Tetracycline (TET) and chloramphenicol (CAM) were used as standard controls. Triton X‐100 (1 %) and phosphate buffer solution (PBS) were used as positive and negative controls, respectively. The concentration of compound 5 q used 2.33 %×MIC value. The other compounds and antibiotics were tested in their respective MICs.
Figure 3ROS detection of compounds 5 b, 5 j, and 5 q against S. aureus.
Figure 4a) Time‐based bactericidal activity of compounds 5 b, 5 j, and 5 q to S. aureus. All the experiments carried out in triplicates and are given the mean ±S.D of CFU/mL. b) Images display S. aureus after 24‐h treatment with compounds 5 b, 5 j, and 5 q.
Figure 5Apoptosis and necrosis determination was carried out by Annexin V‐FITC/PI double staining.
Figure 6a) 2D ligand interaction of 5 b with the amino acid active site of 5XEX. b) 3D docking of 5 b (S=−2.41 kcal/mol) in the active site of 5XEX. c) Docking packing illustration of 5 b with their suitable binding pockets of 5XEX.